Drugs / Tetramethylpyrazine nitrone
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04667013 | Sep 2025 → Mar 2026 overdue | — | Guangzhou Magpie Pharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetramethylpyrazine nitrone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04667013 ↗ |
| Known as | TBN | “Tetramethylpyrazine nitrone (TBN) tablet / Placebo” NCT04667013 ↗ |
| Route | Oral | “Subjects will be administered multiple oral doses of TBN or matching placebo tablets twice a day for 6 consecutive days and a last dose in the morning of Day 7.” NCT04667013 ↗ |